TBPH Long Call Strategy

TBPH (Theravance Biopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited.

TBPH (Theravance Biopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $859.4M, a trailing P/E of 7.46, a beta of 0.19 versus the broader market, a 52-week range of 8.4-21.03, average daily share volume of 620K, a public-listing history dating back to 2014, approximately 97 full-time employees. These structural characteristics shape how TBPH stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.19 indicates TBPH has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 7.46 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.

What is a long call on TBPH?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current TBPH snapshot

As of May 15, 2026, spot at $16.41, ATM IV 101.70%, IV rank 24.62%, expected move 29.16%. The long call on TBPH below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on TBPH specifically: TBPH IV at 101.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a TBPH long call, with a market-implied 1-standard-deviation move of approximately 29.16% (roughly $4.78 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TBPH expiries trade a higher absolute premium for lower per-day decay. Position sizing on TBPH should anchor to the underlying notional of $16.41 per share and to the trader's directional view on TBPH stock.

TBPH long call setup

The TBPH long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TBPH near $16.41, the first option leg uses a $16.41 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TBPH chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TBPH shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$16.41N/A

TBPH long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

TBPH long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on TBPH. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on TBPH

Long calls on TBPH express a bullish thesis with defined risk; traders use them ahead of TBPH catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

TBPH thesis for this long call

The market-implied 1-standard-deviation range for TBPH extends from approximately $11.63 on the downside to $21.19 on the upside. A TBPH long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current TBPH IV rank near 24.62% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on TBPH at 101.70%. As a Healthcare name, TBPH options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TBPH-specific events.

TBPH long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TBPH positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TBPH alongside the broader basket even when TBPH-specific fundamentals are unchanged. Long-premium structures like a long call on TBPH are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current TBPH chain quotes before placing a trade.

Frequently asked questions

What is a long call on TBPH?
A long call on TBPH is the long call strategy applied to TBPH (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With TBPH stock trading near $16.41, the strikes shown on this page are snapped to the nearest listed TBPH chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are TBPH long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the TBPH long call priced from the end-of-day chain at a 30-day expiry (ATM IV 101.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a TBPH long call?
The breakeven for the TBPH long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TBPH market-implied 1-standard-deviation expected move is approximately 29.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on TBPH?
Long calls on TBPH express a bullish thesis with defined risk; traders use them ahead of TBPH catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current TBPH implied volatility affect this long call?
TBPH ATM IV is at 101.70% with IV rank near 24.62%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related TBPH analysis